Stanislas Veillet, President and CEO of Biophytis, said: “Covid-19 has completely transformed our societyon a global scale, and has had a devastating effect particularly on the frail elderly. We are very eager to answer the calls from our industry and national and international organizations to join the global effort to fight this pandemic. Sarconeos (BIO101) has been shown to restore normal respiratory function in several experimental models by activating the renin-angiotensin system, the very one which is attacked by the SARS-Cov-2 virus. In the absence of a suitable vaccineoraproven antiviral therapy we believe that Sarconeos (BIO101)could offer an important potential treatment optionfor patients with acute respiratory failureassociated with COVID-19,potentially limiting the need for ventilators and speeding up their potentialrecovery. We anticipate an approval fromthe ANSM (andpotentiallyother regulatory bodies)to enable us tostart our COVA program, allowing us torespond as quickly as possible to this health emergency.“